title: Response to HBV vaccine in relation to vaccine dose and anti-HCV positivity: a New South Wales correctional facilities' study.
abstract: Currently, about two-thirds of inmates in NSW correctional facilities have a history of injection drug use, and about half have serological evidence of exposure to hepatitis C virus. The introduction of an accelerated hepatitis B vaccination program (0-1-2 months) in 1998, using a 20 microg/dose vaccine was necessitated by the need to vaccinate eligible inmates in this high-risk environment characterised by rapid client mobility. Since 1999, both 10 and 20 microg doses of vaccine were introduced. We found that sero-response rates were not significantly influenced by HCV antibody status, but were significantly lower in cohorts of inmates vaccinated with the 10 microg dose of vaccine.
authors.affiliation: New South Wales Corrections Health Service, P.O. Box 150, NSW 2036, Matraville, Australia. niyiawofeso@hotmail.com
authors.forename: N
authors.initials: N
authors.lastname: Awofeso
authors.forename: M
authors.initials: M
authors.lastname: Levy
authors.forename: S
authors.initials: S
authors.lastname: Harper
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Hayes
authors.forename: J
authors.initials: J
authors.lastname: Douglas
authors.forename: M
authors.initials: M
authors.lastname: Fisher
authors.forename: D
authors.initials: D
authors.lastname: Folpp
mesh_terms: D004306:Dose-Response Relationship, Immunologic; D017325:Hepatitis B Vaccines / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D014611:Vaccination
chemical_list: D017325:Hepatitis B Vaccines; D018937:Hepatitis C Antibodies